•  
  •  
image-723919-Mission_AD_logo.jpg
                       


image-901944-AHEAD-Logo-CMYK-Study-Tagline-1-6512b.png
              

          NCT04468659

What follows is a brief summary of the AHEAD Phase 3 AHEAD trial testing whether the study drug, BAN2401, reduces brain amyloid buildup in people with increased risk of Alzheimer's disease 

  • Drug administration --  IV every 2 weeks   

  • Age range -- 55-80

  • MMSE range -- greater than or equal to 27

  • Study Duration -- 6-7 years

  • Target population -- cognitive normal people who have increased risk of Alzheimer's and a study partner                                                                    

  • Mechanism of action --  reduces brain amyloid buildup

  • Randomization split -- 1:1,  active : placebo

  • Type(s) of imaging -- amyloid PET, Tau PET


For more details on this specific trial, visit:


For more details on the pre-clinical requirements, visit:

ClinicalTrials.gov
                                                                         
             A service of the U.S. National Institutes of Health

Created By Website Builder

Site Map

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060